Journal
CANCER LETTERS
Volume 332, Issue 1, Pages 102-109Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.01.022
Keywords
Deguelin; Breast cancer; Apoptosis; IGFR signaling; IGFBP-3
Categories
Funding
- National Institutes of Health [R01 CA100816]
- National Research Foundation of Korea (NRF)
- Korean government (MEST) [2012-0005721, 2012-0006019]
- Research Settlement Fund for New Faculty of SNU
- National Research Foundation of Korea [2011-0013927] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
In this study, we investigated the antitumor effects of deguelin in several human breast cancer cells in vitro and in vivo. Deguelin inhibited cell viability and the anchorage-dependent and anchorage-independent colony formation of triple-negative (MDA-MB-231 and MDA-MB-468) and triple-positive (MCF-7) breast cancer cells, and it significantly reduced the growth of MCF-7 cell xenograft tumors. The induction of apoptosis, inhibition of insulin-like growth factor-1 receptor (IGF-1R) signaling activation, and up-regulation of IGF-binding protein-3 (IGFBP-3) expression may be associated with deguelin-mediated antitumor effects. Our findings suggest a potential therapeutic use for deguelin in patients with triple-negative breast cancer and for those with breast cancers who are sensitive to endocrine- and HER2-targeted therapies. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available